Cancer Family
Digestive System Neuroendocrine Neoplasm
CI-CAN-00000164Explore in graph →
Non-malignant76 active trials2 evidence items
- NCIt
- C27721
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000164Explore in graph →
Clinical trials
295 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02788565 | Quality of Life, Treatment Experience and Cost of Treatment With Somatostatin Analogues in Patients With Gastroenteropancreatic Neuroendocrine Tumours(STREET) | completed | — | 156 | IpsenINDUSTRY | 1 | Jun 2, 2020 | clinicaltrials |
| NCT00454363 | Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer | completed | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Apr 3, 2020 |
| clinicaltrials |
| NCT02841865 | Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST Criteria(CRIPNET) | completed | — | 104 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | Mar 24, 2020 | clinicaltrials |
| NCT02101918 | Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Mar 23, 2020 | clinicaltrials |
| NCT04065165 | Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome(TELEFIRST) | withdrawn | Phase 3 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Feb 5, 2020 | clinicaltrials |
| NCT04185350 | Clinical Evaluation of 68Ga-NOTA-MAL-Cys39-exendin-4 Positron Emission Tomography in the Detection of Insulinoma | unknown | Early Phase 1 | 60 | Nanjing First Hospital, Nanjing Medical UniversityOTHER | 1 | Dec 4, 2019 | clinicaltrials |
| NCT04134832 | Study of Pancreatic Neuroendocrine Tumors and Carcinomas in Alsace Region | unknown | — | 250 | University Hospital, Strasbourg, FranceOTHER | 1 | Oct 22, 2019 | clinicaltrials |
| NCT02162446 | 68Ga-OPS202 Study for Diagnostic Imaging of GEP NET | completed | Phase 1 / Phase 2 | 12 | IpsenINDUSTRY | 1 | Oct 2, 2019 | clinicaltrials |
| NCT03053999 | Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET) | unknown | — | 53 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT01648465 | Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors | terminated | Phase 2 | 25 | Hellenic Cooperative Oncology GroupOTHER | 1 | Sep 3, 2019 | clinicaltrials |
| NCT00428220 | A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. | completed | N/A | 223 | PfizerINDUSTRY | 17 | Jun 27, 2019 | clinicaltrials |
| NCT01603004 | Potential Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors | completed | — | 25 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 25, 2019 | clinicaltrials |
| NCT03982264 | Endoscopic Treatment of Rectal Neuroendocrine Tumor(NET) Less Than 10mm | unknown | N/A | 90 | Nanfang Hospital, Southern Medical UniversityOTHER | 0 | Jun 11, 2019 | clinicaltrials |
| NCT03963193 | Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type | unknown | Phase 2 | 112 | Henan Cancer HospitalOTHER_GOV | 0 | May 24, 2019 | clinicaltrials |
| NCT02231762 | Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET(SONNET) | completed | Phase 2 | 57 | IpsenINDUSTRY | 2 | May 6, 2019 | clinicaltrials |
| NCT03930368 | Application of Raw Corn Starch on Patients With Insulinoma | unknown | N/A | 20 | Peking Union Medical College HospitalOTHER | 1 | Apr 29, 2019 | clinicaltrials |
| NCT03884179 | Diagnosis of PCL With EUS-FNA and Cross-sectional Imaging - A Report of Accuracy | unknown | — | 58 | Sahlgrenska University HospitalOTHER | 0 | Mar 21, 2019 | clinicaltrials |
| NCT01010126 | Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer | completed | Phase 2 | 252 | National Cancer Institute (NCI)NIH | 2 | Jan 25, 2019 | clinicaltrials |
| NCT03811379 | Toripalimab as Monotherapy for Patients With Small Cell Carcinoma of Esophagus Who Failed Chemotherapy | unknown | Phase 2 | 43 | Sun Yat-sen UniversityOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT03812939 | Recurrence Rates of Type I Gastric Neuroendocrine Tumors Treated With Long-acting Somatostatin Analogs | unknown | — | 30 | Peking Union Medical College HospitalOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT01994213 | A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor | terminated | Phase 2 | 53 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 22, 2019 | clinicaltrials |
| NCT03017690 | Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) | completed | — | 22 | IpsenINDUSTRY | 1 | Dec 21, 2018 | clinicaltrials |
| NCT00019474 | Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer | completed | Phase 2 | 60 | Montefiore Medical CenterOTHER | 1 | Sep 14, 2018 | clinicaltrials |
| NCT03442959 | Resection of the Primary Tumor vs no Resection in Asymptomatic Patients With Unresectable Synchronous Liver Metastases From siNEN(SI-NET) | unknown | — | 50 | CHU de ReimsOTHER | 1 | Jul 12, 2018 | clinicaltrials |
| NCT01024387 | AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors | completed | Phase 2 | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 8, 2018 | clinicaltrials |
| NCT03435770 | Evaluation of Safety and Feasibility of EUS-guided RFA for Solid Pancreatic Neoplasms | unknown | N/A | 10 | Singapore General HospitalOTHER | 1 | Feb 20, 2018 | clinicaltrials |
| NCT03417843 | Safety and Efficacy of an Ablation Catheter for the Treatment of Pancreatic Premalignant Cyctic Lesions.(yes) | unknown | N/A | 20 | HaEmek Medical Center, IsraelOTHER | 0 | Feb 13, 2018 | clinicaltrials |
| NCT02806648 | A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)(PALBONET) | completed | Phase 2 | 21 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT00903396 | Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer | terminated | Phase 2 | 7 | Alliance for Clinical Trials in OncologyOTHER | 1 | Nov 24, 2017 | clinicaltrials |
| NCT02215447 | A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas(NABNEC) | unknown | Phase 2 | 4 | Barwon HealthOTHER_GOV | 1 | Nov 22, 2017 | clinicaltrials |
| NCT02831179 | Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor | withdrawn | Phase 1 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Sep 28, 2017 | clinicaltrials |
| NCT00730483 | Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors | terminated | N/A | 13 | Yale UniversityOTHER | 1 | Aug 25, 2017 | clinicaltrials |
| NCT01980732 | 68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors | no longer available | — | — | Andrei IagaruOTHER | 1 | Aug 23, 2017 | clinicaltrials |
| NCT02108782 | Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors | withdrawn | Phase 2 | 0 | Academic and Community Cancer Research UnitedOTHER | 0 | Jul 19, 2017 | clinicaltrials |
| NCT00001191 | The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid | completed | Phase 2 | — | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT03204019 | A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor | unknown | Phase 2 | 60 | Chinese Academy of Medical SciencesOTHER | 1 | Jun 29, 2017 | clinicaltrials |
| NCT03033186 | Everolimus TDM to Predict Long Term Toxicity(Foresight) | unknown | — | 40 | Maastricht University Medical CenterOTHER | 1 | May 31, 2017 | clinicaltrials |
| NCT00654160 | Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer | completed | Phase 1 | 7 | Mayo ClinicOTHER | 1 | May 25, 2017 | clinicaltrials |
| NCT02685553 | Near Infrared Technology and Laparoscopic Resection of Pancreatic Lesions: the COLPAN Project | completed | Phase 1 | 10 | Universita di VeronaOTHER | 1 | Mar 7, 2017 | clinicaltrials |
| NCT00947167 | A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors | terminated | Phase 2 | 4 | Pamela L. KunzOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT00093782 | Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma | completed | Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2017 | clinicaltrials |
| NCT02273752 | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer | terminated | Phase 2 | 2 | Emory UniversityOTHER | 1 | Feb 3, 2017 | clinicaltrials |
| NCT01374451 | Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET(COOPERATE-2) | terminated | Phase 2 | 160 | Novartis PharmaceuticalsINDUSTRY | 19 | Dec 20, 2016 | clinicaltrials |
| NCT00804336 | Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors | completed | Phase 1 | 22 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 19, 2016 | clinicaltrials |
| NCT02078843 | Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors(GaIN) | terminated | Phase 1 / Phase 2 | 54 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Sep 7, 2016 | clinicaltrials |
| NCT01384617 | Trial Assessing Roux-en-Y Anastomosis of the Pancreatic Stump to Prevent Pancreatic Fistula Following Distal Pancreatectomy | completed | N/A | 136 | Wakayama Medical UniversityOTHER | 1 | Jul 21, 2016 | clinicaltrials |
| NCT01204476 | Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma | completed | Phase 1 | 27 | National Cancer Institute (NCI)NIH | 1 | Jul 15, 2016 | clinicaltrials |
| NCT00049023 | Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors | completed | Phase 1 | 27 | O'Dorisio, M SOTHER | 1 | Jun 21, 2016 | clinicaltrials |
| NCT01155258 | Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors | completed | Phase 1 | 19 | University of Southern CaliforniaOTHER | 1 | Jun 13, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Jun 2, 2020source: clinicaltrials